NASDAQ: THRNThorne Healthtech Inc Stock
$4.62-0.29 (-5.91%)
Updated Mar 31, 2023
THRN Price
$4.62
Fair Value Price
N/A
Market Cap
$247.41M
52 Week Low
$3.41
52 Week High
$7.38
P/E
15.4x
P/B
1.71x
P/S
0.84x
PEG
0.18x
Dividend Yield
N/A
Revenue
$228.73M
Earnings
$15.67M
Gross Margin
50.2%
Operating Margin
3.67%
Profit Margin
6.9%
Debt to Equity
0.57
Operating Cash Flow
$5M
Beta
0.94
Next Earnings
May 10, 2023
Ex-Dividend
N/A
Next Dividend
N/A
THRN Overview
Thorne HealthTech Incorporated is a health and wellness company in the U.S. and internationally. It offers various health tests and offers nutritional supplements and wellness education. The company uses its Onegevity platform to describe the state of an individual's health. Thorne HealthTech was founded in 1984 and is headquartered in New York, NY.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how THRN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
THRN ($4.62) is trading below its intrinsic value of $10.68, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
THRN is good value based on its earnings relative to its share price (15.4x), compared to the US market average (22.13x)
P/E vs Market Valuation
THRN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more THRN due diligence checks available for Premium users.
Be the first to know about important THRN news, forecast changes, insider trades & much more!
THRN News
Valuation
THRN fair value
Fair Value of THRN stock based on Discounted Cash Flow (DCF)
Price
$4.62
Fair Value
$4.08
Overvalued by
13.33%
THRN ($4.62) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
THRN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
15.4x
Industry
20.18x
Market
22.13x
THRN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
THRN is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
THRN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.71x
Industry
2.41x
THRN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
THRN price to earnings growth (PEG)
For valuing profitable companies with growth potential
THRN is good value based... subscribe to Premium to read more.
PEG Value Valuation
THRN's financial health
Profit margin
Revenue
$59.6M
Net Income
$12.5M
Profit Margin
21.1%
THRN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
THRN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$229.8M
Liabilities
$83.2M
Debt to equity
0.57
THRN's short-term assets ($116.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
THRN's short-term assets ($116.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
THRN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$14.0M
Investing
-$12.0M
Financing
$11.2M
THRN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
THRN vs Food Stocks
Thorne Healthtech Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.